Loading stock data…
XBIT
$2.55-0.02 (-0.78%)
After Hours$2.55+0.00 (+0.00%)· Last close May 1
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
XBiotech Inc. in the Healthcare sector is trading at $2.55. The stock is currently 29% below its 52-week high of $3.61, remaining 1.2% below its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why XBIT maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.55
Potential Upside
5%
Whystock Fair Value$2.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also deve...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$77.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.77%
Volume
Today's trading volume
9,806
Recent News
XBiotech: Q4 Earnings Snapshot
AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Friday reported a loss of $26.9 million in its fourth quarter. On a per-share basis, the Austin, Texas-based company said it had a loss of 88 cents.
3 Promising Penny Stocks With Market Caps Over $30M
Major stock indexes in the United States have recently experienced a surge, driven by gains in technology shares and positive economic indicators. While the term "penny stocks" might seem outdated, it still refers to shares of smaller or newer companies that can offer significant potential for growth. By focusing on those with solid financial foundations, investors can uncover opportunities that may provide stability and upside potential.
November 2025's Promising Penny Stocks To Watch
As the Dow Jones Industrial Average reaches an all-time high amid optimism over the potential end of a prolonged U.S. government shutdown, investors are keenly observing market dynamics and seeking opportunities across various sectors. Penny stocks, often seen as a gateway to investing in smaller or emerging companies, continue to hold allure for those looking for growth at accessible price points. Despite their historical reputation for volatility, penny stocks with strong financials and...
XBiotech: Q3 Earnings Snapshot
AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Wednesday reported a loss of $6 million in its third quarter. The Austin, Texas-based company said it had a loss of 20 cents per share.
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
Key Insights Significant control over XBiotech by retail investors implies that the general public has more power to...